Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Essen Biotech
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Wake Forest University Health Sciences
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Southern California
Case Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation
AVM Biotechnology Inc
Arcus Biosciences, Inc.
University of Alabama at Birmingham
IGM Biosciences, Inc.
Cedars-Sinai Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cyteir Therapeutics, Inc.
National Cancer Institute (NCI)
Actuate Therapeutics Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
Centre Hospitalier Henri Duffaut - Avignon
Celldex Therapeutics
OHSU Knight Cancer Institute
Stanford University
Cellestia Biotech AG
Corvus Pharmaceuticals, Inc.
Biologics & Biosimilars Collective Intelligence Consortium
Eastern Cooperative Oncology Group
Case Comprehensive Cancer Center
AbbVie
Institut Bergonié
Auxilio Mutuo Cancer Center
Eli Lilly and Company
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Amgen
sigma-tau i.f.r. S.p.A.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
European Organisation for Research and Treatment of Cancer - EORTC